ShockWave Medical Q4 2023 GAAP EPS $1.20 Beats $0.90 Estimate, Sales $202.98M Beat $199.45M Estimate
Portfolio Pulse from Benzinga Newsdesk
ShockWave Medical (NASDAQ:SWAV) reported Q4 2023 earnings of $1.20 per share, surpassing the $0.90 estimate, with sales of $202.98M exceeding the $199.45M forecast. This represents a 40.93% increase in sales compared to the same period last year.
February 15, 2024 | 9:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ShockWave Medical reported a significant beat on both earnings and sales estimates for Q4 2023, with a notable year-over-year sales increase.
ShockWave Medical's earnings and sales beat are likely to positively impact investor sentiment and the stock price in the short term. The significant year-over-year sales growth further underscores the company's strong performance and may lead to increased investor confidence.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100